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Abstract 41 
The genomic complexity of profound copy-number aberration has prevented effective molecular 42 
stratification of ovarian cancers. To decode this complexity, we derived copy-number signatures 43 
from shallow whole genome sequencing of 117 high-grade serous ovarian cancer (HGSOC) 44 
cases, which were validated on 527 independent cases. We show that HGSOC comprises a 45 
continuum of genomes shaped by multiple mutational processes that result in known patterns of 46 
genomic aberration. Copy-number signature exposures at diagnosis predict both overall survival 47 
and the probability of platinum-resistant relapse. Measuring signature exposures provides a 48 
rational framework to choose combination treatments that target multiple mutational processes. 49 
 50 
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The discrete mutational processes that drive copy-number change in human cancers are not 58 
readily identifiable from genome-wide sequence data. This presents a major challenge for the 59 
development of precision medicine for cancers that are strongly dominated by copy-number 60 
changes, including high-grade serous ovarian (HGSOC), esophageal, non-small-cell lung and 61 
triple negative breast cancers1. These tumors have low frequency of recurrent oncogenic 62 
mutations, few recurrent copy number alterations, and highly complex genomic profiles2. 63 
HGSOCs are poor prognosis carcinomas with ubiquitous TP53 mutation3. Despite efforts to 64 
discover new molecular subtypes and targeted therapies, overall survival has not improved over 65 
two decades4. Current genomic stratification is limited to defining homologous recombination-66 
deficient (HRD) tumors5-7 with approximately 20% HGSOC cases having a germline or somatic 67 
mutation in BRCA1/2 with smaller contributions from mutation or epigenetic silencing of other HR 68 
genes8. Classification using gene expression predominantly reflects the tumor microenvironment 69 
and is reliable in only a subset of patients9-11. Detailed genomic analysis using whole genome 70 
sequencing has shown frequent loss of RB1, NF1 and PTEN by gene breakage events12 and 71 
enrichment of amplification associated fold-back inversions in non-HRD tumors13. However, none 72 
of these approaches has provided a broad mechanistic understanding of HGSOC, reflecting the 73 
challenges of detecting classifiers in extreme genomic complexity. 74 
Recent algorithmic advances have enabled interpretation of complex genomic changes by 75 
identifying mutational signatures — genomic patterns that are the imprint of mutagenic processes 76 
accumulated over the lifetime of a cancer cell14. For example, UV exposure or mismatch repair 77 
defects induce distinct, detectable single nucleotide variant (SNV) signatures14. The clinical utility 78 
of these signatures has recently been demonstrated through a combination of structural variant 79 
(SV) and SNV signatures to improve the prediction of HRD15. Importantly, these studies show that 80 
tumor genomes are shaped by multiple mutational processes and novel computational approaches 81 
are needed to identify coexistent signatures. We hypothesized that specific features of copy-82 
number abnormalities could represent the imprints of distinct mutational processes, and developed 83 
methods to identify signatures from copy-number features in HGSOC. 84 
  85 
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  87 
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Results 89 
Experimental design and data collection 90 
We generated absolute copy number profiles from 253 primary and relapsed HGSOC samples 91 
from 132 patients in the BriTROC-1 cohort16 using low-cost shallow whole-genome sequencing 92 
(sWGS; 0.1×) and targeted amplicon sequencing of TP53 (Supplementary Figure 1). These 93 
samples formed the basis of our copy-number signature identification. A subset of 56 of these 94 
cases had deep whole-genome sequencing (dWGS) performed for mutation analysis and 95 
comparison with sWGS data. Independent data sets for validation included 112 dWGS HGSOC 96 
cases from PCAWG17 and 415 HGSOC cases with SNP array and whole exome sequence from 97 
TCGA8. Supplementary Figure 1a shows the REMARK diagram for selection of BriTROC-1 98 
patients. Supplementary Figure 1b outlines which samples were used in each analysis across the 99 
three cohorts. Clinical data for the BriTROC-1 cohort are summarized in Supplementary Table 1 100 
and Supplementary Figure 2.  101 
Identification and validation of copy-number signatures 102 
To identify copy-number (CN) signatures, we computed the genome-wide distributions of six 103 
fundamental CN features for each sample: the breakpoint count per 10MB, the copy-number of 104 
segments, the difference in CN between adjacent segments, the breakpoint count per 105 
chromosome arm, the lengths of oscillating CN segment chains and the size of segments. These 106 
features were selected as hallmarks of previously reported genomic aberrations, including 107 
breakage-fusion-bridge cycles18, chromothripsis19 and tandem duplication20,21.  108 
We applied mixture modelling to separate the copy-number feature distributions from 91 BriTROC-109 
1 samples with high quality CN profiles into mixtures of Poisson or Gaussian distributions. This 110 
resulted in a total of 36 mixture components (Figure 1a). For each sample, the posterior probability 111 
of copy-number events arising from these components was computed and summed. These sum-112 
of-posterior vectors were then combined to form a sample-by-component sum-of-posteriors matrix. 113 
To identify copy-number signatures, this matrix was subjected to non-negative matrix factorization 114 
(NMF)22, a method previously used for deriving SNV signatures14.  115 
NMF identified seven CN signatures (Figure 1a), as well as their defining features and exposures 116 
in each sample. The optimal number of signatures was chosen using a consensus from 1000 117 
initializations of the algorithm and 1000 random permutations of the data combining four model 118 
selection measures (Supplementary Figure 3). We found highly similar component weights for the 119 
signatures in the two independent cohorts (PCAWG-OV and TCGA), demonstrating the robustness 120 
of both the methodology and the copy-number features (Figure 1b, P<9e-05, median r=0.86. 121 
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Supplementary Table 2), despite a significant difference in exposures to CN signatures 2, 3, 4 and 122 
5 between the cohorts (P<0.05, two-sided Wilcoxon rank sum test, Supplementary Figure 4).  123 
Linking copy-number signatures with underlying mutational processes 124 
The majority of cases analysed exhibited multiple signature exposures suggesting that HGSOC 125 
genomes are shaped by more than one mutational process. As our signature analysis reduced this 126 
genomic complexity into its constituent components, we were able to link the individual copy-127 
number signatures to their underlying mutational processes. To do this, we used the component 128 
weights identified by NMF to determine which pattern of global or local copy-number change 129 
defined each signature. For example, for CN signature 1, the highest weights were observed for 130 
components representing low numbers of breakpoints per 10MB, long genomic segments and two 131 
breaks occurring per chromosome arm (Figure 2a, Supplementary Figure 5). Two breaks per 132 
chromosome arm suggested that the mutational process underlying this signature might be 133 
breakage-fusion-bridge (BFB) events18.  134 
To test this hypothesis, we correlated CN signature 1 exposures with mutation data, SNV 135 
signatures, and other measures derived from deep WGS and exome sequencing (Figure 2b-e, 136 
Supplementary Figures 6, 7, 8 and 9, Supplementary Tables 3, 4, 5, 6, 7 and 8). CN signature 1 137 
was anti-correlated with sequencing estimates of telomere length (r=-0.32, P=0.009), consistent 138 
with BFB events. In addition, CN signature 1 was positively correlated with amplification-139 
associated fold-back inversion structural variants (r=0.36, P=0.02), which have been strongly 140 
implicated in BFB events23 and have also been associated with inferior survival in HGSOC13. CN 141 
signature 1 was also enriched in cases with oncogenic RAS signaling, including NF1 loss and 142 
mutated KRAS (p=5e-06, Mann-Whitney test), which has previously been shown to induce 143 
chromosomal instability as a result of aberrant G2 and mitotic checkpoint controls and 144 
missegregation24,25. Taken together, these data provide independent evidence for BFB arising as a 145 
result of oncogenic RAS signaling and telomere shortening as the underlying mechanism for CN 146 
signature 1. 147 
We applied these approaches to the remaining signatures to identify statistically significant 148 
genomic associations using a false discovery rate <0.05 (Figure 2b-e, Figure 3, Supplementary 149 
Figures 5, 6, 7, 8 and 9, Supplementary Tables 3, 4, 5, 6, 7 and 8).  150 
CN signature 2 showed frequent breakpoints per 10MB, single changes in copy-number (resulting 151 
in 3 copies), chains of oscillating copy-number, and was significantly correlated with tandem 152 
duplicator phenotype scores (r=0.3, P=0.004) and SNV signature 5 (r=0.26, P=0.02). In addition, 153 
this signature was enriched in patients with mutations in CDK12 (P=0.02, Mann-Whitney test, 154 
Supplementary Table 6), in keeping with previous studies that have demonstrated large tandem 155 
duplication in cases with inactivating CDK12 mutations26.  156 
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CN signature 4 was characterised by high copy-number states (4-8 copies) and predominant copy-157 
number change-points of size 2. This pattern indicates a mutational process of late whole-genome 158 
duplication (WGD)27. Significantly increased signature 4 exposure in cases with aberrant PI3K/AKT 159 
signaling provided further support for late WGD as oncogenic PIK3CA induces tolerance to 160 
genome doubling28 (P=2e-22, Mann-Whitney test, mutation of PIK3CA or amplification of AKT, 161 
EGFR, MET, FGFR3 and ERBB2). Signature 4 was also seen at higher levels in cases with 162 
mutations in Toll-like receptor signaling cascades (P=2e-07), interleukin signaling pathways (P=3e-163 
24) and CDK12 (P=0.0009), as well as those with amplified CCNE1 (P=2e-10) and MYC (P=9e-164 
12). It was also significantly correlated with telomere length (r=0.46, P=4e-05).   165 
CN signature 6 showed extremely high copy-number states and high copy-number change-points 166 
for small segments interspersed among larger, lower-copy segments. This suggests a mutational 167 
process resulting in focal amplification. Increased signature 6 exposure was associated with 168 
mutations across diverse pathways, including aberrant G1/S cell cycle checkpoint control (through 169 
either amplification of CCNE1, CCND1, CDK2, CDK4 or MYC, deletion/inactivation of RB1 or 170 
mutation in CDK12), Toll-like receptor signaling cascades and PI3K/AKT signaling (P<0.05). 171 
However, as many of these statistical associations are marked by gene amplification, it is difficult 172 
to determine whether the copy number states represent causal events or are simply a 173 
consequence of focal amplification. Exposure to CN signature 6 was also positively correlated with 174 
age at diagnosis (r=0.31, P=6e-12) and age-related SNV signature 114 (r=0.43, P=3e-06).  175 
CN signature 5 was significantly associated with predicted chromothriptic-like events using the 176 
Shatterproof algorithm29 (r=0.44, P=2e-03). Chromothripsis is considered rare in HGSOC12,27,30. 177 
However, the key component of this signature—the presence of copy-number change points 178 
centered at 0.5 copies—suggests that the events are subclonal. This implies that chromothripsis 179 
may be an underestimated oncogenic mechanism in HGSOC that could reflect ongoing formation 180 
and rupture of micronuclei31.  181 
CN signature 3 was characterized by an even distribution of breaks across all chromosomes, and 182 
copy number changes from diploid to single copy (LOH). CN signature 3 was significantly enriched 183 
in cases with mutations in BRCA1 and BRCA2, and other HR genes including BARD1, PALB2 and 184 
ATR (P=0.002, Mann-Whitney test). It was also correlated with the HRD-related SNV signature 3 185 
(r=0.32, P=0.002) and anti-correlated with age at diagnosis and age-related SNV signature 1 186 
(P<0.05). CN signature 3 was also enriched in cases with loss of function mutations in PTEN 187 
(P=0.002, Mann-Whitney test). Taken together, these data suggest that CN signature 3 is driven 188 
by BRCA1/2-related HRD mechanisms.  189 
CN signature 7, like CN signature 3, also demonstrated an even distribution of breaks across all 190 
chromosomes. By contrast with CN signature 3, single copy-number changes were observed from 191 
a tetraploid rather than a diploid state (Figure 3). Although there was correlation with the HRD-192 
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related SNV signature 3, there was no enrichment with BRCA1/2 mutation, suggesting alternative 193 
HRD mechanisms as potential mutational processes.  194 
We also investigated relationships between CN signatures. BRCA1 dysfunction and CCNE1 195 
amplification have been shown to be mutually exclusive in HGSOC32, and we observed that CN 196 
signature 3 (BRCA1/2 HRD) and CN signature 6 (marked by aberrant G1/S cell cycle checkpoint 197 
control) showed mutually exclusive associations (Figure 2b-e). Loss of BRCA1 and BRCA2 are 198 
early driver events in HGSOC, and to investigate acquisition of additional mutational processes, 199 
we studied four BriTROC-1 cases with deleterious germline BRCA2 mutations and confirmed 200 
somatic loss of heterozygosity at BRCA2 (Figure 4). A diverse and variable number of CN 201 
signatures was seen in these cases, including substantial exposures to CN signature 1 (RAS 202 
signaling) in three of the four cases.  203 
Copy-number signatures predict overall survival 204 
We next explored the association between individual CN signature exposures and overall survival 205 
using a combined dataset of 575 diagnostic samples with clinical outcomes. We trained a 206 
multivariate Cox proportional hazards model on 417 cases and tested this on the remaining 158 207 
cases (Figure 5, Supplementary Table 9). CN signature exposure was significantly predictive of 208 
survival (Training: P=0.002, log-rank test; stratified by age and cohort; Test: P=0.05,  C-209 
index=0.56, 95% CI:0.50-0.62; Entire cohort: P=0.002, log-rank test; stratified by age and cohort). 210 
Across the entire cohort, poor outcome was significantly predicted by CN signature 1 (P=0.0008) 211 
and CN signature 2 exposures (P=0.03), whilst good outcome was significantly predicted by 212 
exposures to CN signatures 3 (P=0.05) and 7 (P=0.006). 213 
Unsupervised hierarchical clustering of samples by signature exposures identified three clusters 214 
(Figure 5). Despite showing significant survival differences (P=0.004, log-rank test; stratified by 215 
age and cohort), these clusters did not provide any prognostic information in addition to that 216 
identified from the Cox proportional hazards model; cluster 2 was dominated by patients with high 217 
signature 1 exposures (poor prognosis), cluster 3 showed high signature 3 exposures (good 218 
prognosis) and cluster 1 had mixed signature exposures (Supplementary Figure 10).   219 
Copy-number signatures indicate relapse following chemotherapy 220 
Using a generalised linear model, we investigated whether copy-number signatures could be used 221 
to predict outcome following chemotherapy across 36 patients from the BriTROC-1 study with 222 
paired diagnostic and relapse samples16. The model showed CN signature 1 exposures at the time 223 
of diagnosis to be significantly predictive of platinum-resistant relapse (P=0.02, z-test, 224 
Supplementary Table 10).  225 
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Using the same 36 sample pairs, we also investigated whether chemotherapy treatment changed 226 
CN signature exposures. No significant effects on exposures were observed following 227 
chemotherapy treatment using a linear model that accounted for signature exposure at time of 228 
diagnosis, number of lines of chemotherapy and patient age (P>0.05, F-test, Supplementary Table 229 
10). The only variable showing a significant association with exposure at relapse was signature 230 
exposure at diagnosis (P<0.01, F-test, Supplementary Table 11).    231 
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Discussion 232 
Copy-number signatures provide a framework that is able to rederive the major defining elements 233 
of HGSOC genomes, including defective HR8, amplification of cyclin E9 and amplification-234 
associated fold-back inversions13. In addition, the CN signatures show significant associations with 235 
known driver gene mutations in HGSOC and provide the ability to detect novel associations with 236 
gene mutations. We derived signatures using inexpensive shallow whole genome sequencing of 237 
DNA from core biopsies. These approaches are rapid and cost effective, thus providing a clear 238 
path to clinical implementation. Copy-number signatures open new avenues for clinical trial design 239 
by highlighting contributions from underlying mutational processes that depend on oncogenic RAS 240 
and PI3K/AKT signaling. 241 
We found that almost all patients with HGSOC demonstrated a mixture of signatures indicative of 242 
combinations of mutational processes. These results suggest that early TP53 mutation, the 243 
ubiquitous initiating event in HGSOC, may permit multiple mutational processes to co-evolve, 244 
potentially simultaneously. Although further work is needed to define the precise timing of 245 
signature exposures, early driver events such as BRCA2 mutation still permit a diverse and 246 
variable number of CN signatures in addition to an HRD signature (Figure 4). These additional 247 
signature exposures may alter the risk of developing therapeutic resistance, particularly when only 248 
a single mutational process such as HRD is targeted. 249 
High exposure to CN signature 3, characterised by BRCA1/2-related HRD, is associated with 250 
improved overall survival, confirming prior data showing that BRCA1/2 mutation is associated with 251 
long survival in HGSOC33,34. Conversely, high exposure to signature 1, which is characterised by 252 
oncogenic RAS signaling (including NF1, KRAS and NRAS mutation), predicts subsequent 253 
platinum-resistant relapse and poor survival. This suggests that powerful intrinsic resistance 254 
mechanisms are present at the time of diagnosis and can be readily identified using CN signature 255 
analysis. This hypothesis is supported by the presence of exposure to CN signature 1 in germline 256 
BRCA2-mutated cases (Figure 4) as well as our previous work demonstrating the expansion of a 257 
resistant subclonal NF1-deleted population following chemotherapy treatment in HGSOC35 and 258 
poor outcomes in Nf1-deleted murine models of HGSOC36. Our CN signature analysis of BRCA2-259 
mutated cases also concurs with PCAWG/ICGC data showing that over half (9/16) of NF1-mutated 260 
cases also harboured mutations in BRCA1 or BRCA212. These data suggest a complex interplay 261 
between RAS signaling and HRD. Thus, RAS signaling may be an important target, especially in 262 
first line treatment, to prevent emergence of platinum-resistant disease. 263 
We found that CN signature exposures were not significantly altered between diagnosis and 264 
disease relapse in 36 sample pairs with a median interval of 30.6 months16. This suggests that the 265 
underlying mutational processes in HGSOC are relatively stable and that genome-wide patterns of 266 
copy-number change mainly reflect historic alterations to the genome acquired during 267 
 10 
tumorigenesis37. Relative invariant genomic changes were also observed in the ARIEL2 trial, 268 
where genome-wide loss-of-heterozygosity was used to predict HRD, and only 14.5% (17/117) 269 
cases changed LOH status between diagnosis and relapse7.  270 
Larger association studies will be required to further refine CN signature definitions and 271 
interpretation. The application of our approach to other tumour types is likely to extend the set of 272 
signatures beyond the robust core set identified here. Basal-like breast cancers, squamous cell 273 
and small cell lung carcinoma, which all have high rates of TP53 mutation and genomic instability2, 274 
are promising next targets. Although it is likely that the strong associations have identified the 275 
driver mutational processes for CN signatures 1 and 3, functional studies will be required to 276 
establish causal links for the remaining signatures. For example, CN signature 6 was significantly 277 
associated with multiple mutated pathways, and this association was primarily driven by 278 
amplification of target genes. As this signature represented focal amplification events, it is difficult 279 
to determine whether amplification of specific genes drives the underlying mutational process or 280 
the amplifications emerge as a consequence of strong selection of advantageous phenotypes. Our 281 
data does not provide timing information for exposures and there is the real possibility that one 282 
mutational process may well drive the emergence of other mutational processes. For example, the 283 
association between signature 6 and PI3K signalling is also shared with signature 4. 284 
Other limitations of this work are technical: we integrated data from three sources, using three 285 
different pre-processing pipelines, and the ploidy determined by different pipelines can have a 286 
significant effect on the derived signatures. For example, high-ploidy CN signature 4 was 287 
predominantly found in the sequenced samples that underwent careful manual curation to identify 288 
whole-genome duplication events. When extending to larger sample sets, a unified processing 289 
strategy with correct ploidy determination is likely to produce improved signature definitions.  290 
Efforts to identify discrete, clinically relevant subtypes of disease have been successful in many 291 
cancer types38-40. However, HGSOC lacks clinically-relevant patient stratification, which is reflected 292 
in continued poor survival. We show that HGSOC genomes are shaped by multiple mutational 293 
processes that preclude simple subtyping. Thus, our results suggest that HGSOC is a continuum 294 
of genomes. By dissecting the mutational forces shaping HGSOC genomes, our study paves the 295 
way to understanding extreme genomic complexity, as well as revealing the evolution of tumors as 296 
they relapse and acquire resistance to chemotherapy.   297 
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Figure Legends 332 
Figure 1 | Copy-number signature identification from shallow whole genome sequence data 333 
and validation in independent cohorts 334 
a. Step 1: Absolute copy-numbers are derived from sWGS data; Step 2: genome-wide distributions 335 
of six fundamental copy-number features are computed; Step 3: Gaussian or Poisson mixture 336 
models (depending on data type) are fitted to each distribution and the optimal number of 337 
components is determined (ranging from 3–10) ; Step 4: the data are represented as a matrix with 338 
36 mixture component counts per tumor. Step 5: Non-negative matrix factorization is applied to the 339 
components-by-tumor matrix to derive the tumor-by-signature matrix and the signature-by-340 
components matrix. 341 
b. Heat maps show component weights for copy number signatures in two independent cohorts of 342 
HGSOC samples profiled using WGS and SNP array. Correlation coefficients are provided in 343 
Supplementary Table 2. 344 
Figure 2 | Linking copy-number signatures with mutational processes 345 
a Component weights for copy number signature 1. Barplots (upper panel) are grouped by copy 346 
number feature and show weights for each of the 36 components. The middle panel shows the 347 
mixture models of each distribution with components defining CN signature 1 highlighted in color. 348 
Lower panel shows genome-wide distribution (density) of each copy number feature, across the 349 
BriTROC-1 cohort, weighted by signature exposure. (Note: similar plots for other CN signatures 350 
are shown in Figure 3 and Supplementary Figure 5). 351 
b Associations between CN signature exposures and other features. Purple indicates positive 352 
correlation and orange negative correlation (see also Supplementary Figure 6). Numbers at the 353 
right of the panel indicate cases included in each analysis. Only significant correlations are shown 354 
(P<0.05). 355 
c Associations between CN signature exposures and SNV signatures. Purple indicates positive 356 
correlation and orange negative correlation (see also Supplementary Figure 6). The number at the 357 
right of the panel indicates cases included in the analysis. 358 
d and e Difference in CN signature exposures between cases with mutations in specific genes (d) 359 
and mutated/wildtype reactome pathways (e). The absolute difference in mean signature 360 
exposures was calculated for cases with and without mutations. Colors in filled circles indicate 361 
extent of difference. Only differences with FDR P<0.05 (Mann-Whitney test) are shown (see also 362 
Supplementary Figure 7).  363 
Numbers at the right of the panel indicate cases with mutations (SNVs, amplifications or deletions) 364 
in each gene/pathway. 365 
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Figure 3 | The seven copy-number signatures in HGSOC  366 
Description of the defining component weights, key associations and proposed mechanisms for the 367 
seven copy number signatures.  368 
*only the top three mutated genes for each of the pathways associated with CN signatures 4, 6 369 
and 7 are shown (the list of all significant genes is provided in Supplementary Tables 7 and 8). 370 
Figure 4 | CN signature exposures of four BriTROC-1 patients with germline BRCA2 371 
mutations and somatic loss of heterozygosity 372 
Stacked bar plots show copy-number signature exposures for four BriTROC-1 cases with 373 
pathogenic germline BRCA2 mutations and confirmed somatic loss of heterozygosity (LOH) at the 374 
BRCA2 locus. 375 
Figure 5 | Association of survival with copy-number signatures 376 
Upper panel: Stacked barplots show CN signature exposures for each patient. Patients were 377 
ranked by risk of death estimated by a multivariate Cox proportional hazards model stratified by 378 
age and cohort, with CN signature exposures as covariates.  379 
Middle panel: Colored matrix indicates group for each patient assigned by unsupervised clustering 380 
of CN signature 1, 2, 3 and 7 exposures (see also Supplementary Figure 10).  381 
Lower panel: Linear fit of signature exposures ordered by risk predicted by the Cox proportional 382 
hazards model. 383 
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